Infections and injection-site reactions are most common.
Immune- and Administration-Related Safety Profile

CAPS: Nasopharyngitis (34%), diarrhea (20%), vertigo (11%), influenza (17%).

TRAPS/HIDS/MKD/FMF: Injection-site reactions (10.1%), nasopharyngitis (10.7%).

Still’s Disease: Upper respiratory infections (54.8%), abdominal pain (14.1%).

Gout Flares: Nasopharyngitis (16.3%), hypertriglyceridemia (2.7%), back pain (3.1%).

Serious Events: Opportunistic infections (e.g., pneumonia), DRESS syndrome (postmarketing).
Hematologic (neutropenia) and hepatic (transaminase elevation) abnormalities were transient.